Alcohol-related cancer deaths have doubled in recent years in the US
The number of annual alcohol deaths due to cancer has doubled in recent years in the U.S., researchers said this week.
The tally rose from 11,896 in 1990 to 23,207 by 2021, according to data that was presented at the American Society of Clinical Oncology 2025 conference.
'Alcohol-associated cancer mortality has significantly increased in the U.S. over the past three decades, with a disproportionate burden observed in males and individuals aged 55 and older,' they wrote.
They reached these conclusions using data from the Global Burden of Disease database, which provides incidence and mortality estimates for 35 cancer types. They found that the rates increased for all cancers combined and specific cancers across both genders and age groups, with the exception of liver cancer in people aged 55 and up.
'In 2021, for [the 55-plus age group], liver cancer had the highest alcohol-associated proportional [mortality rate] in males (38.5 percent), followed by nasopharyngeal cancer (31.8 percent), while in females, nasopharyngeal (18.9 percent) and oro/hypopharyngeal cancers (18.4 percent) ranked highest. In 20-54 age, lip-oral cavity cancer had the highest alcohol-associated proportional [rates] for both genders,' they noted.
The researchers identified Washington, D.C., as the area with the highest rates of alcohol-associated cancer. Utah had the lowest.
An increasing number of women have become heavy drinkers, although alcohol abuse still kills more men than women. While drinking rates dropped from the 1970s through the 1990s, they also rose during the Covid pandemic. So did alcohol-related deaths.
'This is death as opposed to getting a disease. We can treat a lot of cancers, and we're getting better at that, but this is really driving home the point that people are dying from cancer due to alcohol,' said Jane Figueiredo, a professor of medicine at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, who was not involved with the research told NBC News.
The research, which has not yet been published in a peer-reviewed journal, comes after former U.S. Surgeon General Dr. Vivek Murthy issued a call for cancer risk warnings to be included on alcoholic beverages.
"Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States - greater than the 13,500 alcohol-associated traffic crash fatalities per year in the U.S. - yet the majority of Americans are unaware of this risk," he said in a news release earlier in the year.
The researchers cited this warning in their report, noting that alcohol consumption is known to be a significant risk factor for cancer.
The International Agency on Cancer Research, a branch of the World Health Organization, classified alcohol as a carcinogen in 1987, and the organization says there's no safe amount of alcohol consumption.
The Centers for Disease Control and Prevention had previously said that approximately 20,000 adults in the U.S. die from alcohol-associated cancers each year. The agency noted that most of the deaths may have been avoided if all adults had followed the recommended limits on alcohol use.
The authors of the recent research said their findings indicate the need for enhanced prevention.
'Our findings highlight the critical need for targeted prevention efforts, public health policies, and increased awareness to address the rising impact of alcohol consumption on cancer-related mortality across different demographic groups and regions,' they said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
The Hill
3 hours ago
- The Hill
Hundreds of pharmacies are set to close: How it could impact you
(NEXSTAR) — Several retail pharmacy chains have shuttered some of their stores this year, with more on the way for others, like Rite Aid, which filed for bankruptcy in May. It could create what some refer to as 'pharmacy deserts,' areas in which drugstores and the additional services they provide may not be available for miles. And in areas where other pharmacies are picking up the slack, it could have an impact on current customers. 'Closures of major chain pharmacies often create ripple effects across the community,' E. Michael Murphy, an assistant professor of clinical pharmacy at The Ohio State University, told Nexstar via email. Nearby pharmacies, independent or part of a chain, can see 'a sudden increase in patients,' he explained, which could 'lead to longer lines, and increase strain on the health care team.' It could also disrupt your medical care. Shuttering pharmacies in larger cities, like New York City and Philadelphia, may have limited impacts. Take, for example, a Rite Aid located in Philadelphia that has been designated for closure. A three-minute walk down the road will take you to a Walgreens and a local pharmacy. Within smaller communities, that may not be the case. Customers may need to drive to a nearby town to pick up their prescriptions, which 'could have some negative consequences on their adherence to their medication,' Lucas A. Berenbrok, an associate professor at the University of Pittsburgh School of Pharmacy, explained to Nexstar. 'For those without reliable transportation, especially older adults or people with disabilities, traveling even a few extra miles can be a serious barrier,' Murphy said. That could lead to delayed access to prescriptions and missed dosages. Closing pharmacies also reduces health access points for people. In addition to filling prescriptions, pharmacies are able to provide vaccines, chronic disease management, urgent consultations, over-the-counter treatments, and certain health tests. 'There's a lot more going on at the pharmacy now than ever before,' Berenbrok explained, outlining how pharmacists helped to administer the COVID vaccine during the pandemic, for example, and the additional services they can provide in some states. He went on to explain that while online pharmacies can help fill the void of shuttered drugstores, they're largely unable to accommodate the additional services pharmacies provide. 'They also assume reliable internet access, digital literacy, and stable housing, which are barriers for many vulnerable patients,' Murphy said. 'For communities losing local pharmacies, online options may fill part of the gap but cannot replace the full range of services a community pharmacist provides.' Berenbrok agreed that mail-order pharmacies have 'a time and place' because of their convenience, but they require planning ahead, which may not be useful for certain medications like antibiotics. If your pharmacy is closing soon, Murphy recommended being proactive and asking your pharmacist where your prescriptions are being sent and whether that pharmacy has your insurance and medication history. He also encouraged asking for a 90-day supply or mail-order option for prescriptions if transportation is a concern. Chains poised to take on former Rite Aid clients, like CVS and Walgreens, say they're prepared to welcome new customers. Even if your prescriptions are not moving to a new pharmacy, you may want to make sure your prescription is being filled a day or two before you need it rather than the same day that your current supply runs out, Berenbrok said. Then, if you're short on time and facing a long line, you won't miss a dose. Murphy also suggested contacting elected officials and urging them to take action. 'While pharmacists are committed to stepping up to meet the need, without adequate state and federal policy changes to address the broken business model that caused the pharmacy to close in the first place, we will continue to see pharmacies close and patients having to navigate the loss of their trusted health care professional.'
Yahoo
4 hours ago
- Yahoo
Opinion - How thousands of unreviewed ingredients got into our food — and what FDA can do about it
At least 1,000 ingredients in food products on our grocery store shelves have never been checked for safety by the Food and Drug Administration. Dozens have raised serious safety concerns among experts. How did the FDA allow this? The answer can be found in the agency's lax interpretation of a little-known legal designation that lets companies decide for themselves if ingredients in their products are safe. Fortunately, there are steps the agency can take right now to stem the flow of potentially unsafe ingredients into our food supply. Environmental Defense Fund outlined these steps in a letter we recently sent to the agency, but first let's take a closer look at how we got here. 'Generally Recognized as Safe' is a designation Congress created in 1958 to allow commonly used food ingredients to bypass the FDA's pre-market safety review process. It was meant for food substances — such as oils, vinegar, baking soda and common spices — that were widely considered safe due to their long history of everyday use. Since 1958, this status has been coopted to cover a universe of foods that extends far beyond its original intent. According to FDA regulations, a chemical can receive the designation if experts widely agree that scientific evidence shows its use to be safe. But because 'Generally Recognized as Safe' wasn't meant for newer ingredients, Congress allowed ingredients so designated to skip the FDA's premarket approval process — despite requiring similar evidence for other additives. Under the agency's current interpretation, companies can designate the use of a substance as safe and take products with that substance to market without informing the FDA or the public of its decision. While companies may voluntarily submit a notice to FDA offering safety evidence, they are not required to — and often don't. Our organization estimated that manufacturers have notified FDA of fewer than half of the ingredients they market as safe under the 'Generally Recognized' standard. Companies that do bother to submit a notice to the FDA are free to withdraw it at any point and take their product to market, provided they can cite evidence of its safe use. But this 'evidence' is often far from independent. Companies can, and often do, enlist their own employees or handpicked consultants to conduct their safety assessments. The result is a process riddled with conflicts of interest that lets unsafe foods into Americans' homes. We analyzed 'Generally Recognized as Safe' notices received by the FDA, obtained via a Freedom of Information request, and found that of the 1,163 submitted by companies between 1997 and April 2024, 192 were later withdrawn, with safety concerns cited in at least a dozen cases. We also identified 31 ingredients that companies have advertised to be recognized as safe, such as in press releases, trade publications and on their own websites (see the Appendix of our letter). However, we were unable to find the scientific evidence required under this standard to demonstrate these ingredients are commonly regarded as safe among experts. This raises red flags that FDA should be taking seriously. Although a comprehensive fix to the 'Generally Recognized' standard will require legislation from Congress, there are significant steps the FDA can take right away to ensure a more rigorous determination process that better protects Americans' health. Starting today, the FDA can use existing authority to remove safe designations from ingredients it deems unsafe and take them off the market. It can also notify manufacturers, importers, distributors and retailers that the substance is no longer recognized as safe. In addition, the FDA can enforce the requirement that companies base safety designations on publicly available data. Although this won't curtail companies' ability to self-declare substances as safe, it will require those who do to be transparent in citing their evidence. Third, the FDA can enforce the requirement that safety assessments consider vital health information such as a substance's dietary sources, potential cancer risks and the cumulative health effects of similar substances. Finally, the FDA can make companies revise and resubmit their data for review when they submit 'Generally Recognized as Safe' notices that fail to comply with the criteria. The 'Generally Recognized as Safe' designation is far from a perfect system, but it can work better if it is interpreted and enforced more comprehensively. If the FDA is serious about protecting public health, it should start by fully exercising the tools already at its disposal. Maria Doa is senior director at the Chemicals Policy at Environmental Defense Fund. Maricel Maffini is an independent consultant focused on human and environmental health and chemical safety. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
